Published by mark itwired
Posted on September 7, 2021
The rising incidence of non-communicate diseases is creating scope for novel and advanced imaging technologies. There is immense scope for technologies that offer non-invasive yet precise diagnosis of various types of cancer and cardiovascular ailments. Future Market Insights (FMI) sees the prevailing trends to be highly favorable for the expansion of molybdenum-99 market.
Technetium-99m derived from molybdenum-99 (99Mo) is a key isotope used in radionuclide imaging. It is a part of the technology that non-invasively diagnoses regional metabolic and physiologic processes such as blood flow in the heart to zero down on the affected organ or tissue.
Molybdenum-99 is therefore used as radioisotope in various nuclear medicine diagnostic procedures. With several leading healthcare organizations intending to up their research and development initiatives, the 99Mo is expected to grow considerably in the coming years.
FMI in a recent study has projected the market to rise at a CAGR of 5.2% between 2020 and 2030. The rising willingness among patients and their families to spend on advanced healthcare will bode well for the market. Additionally, government support in the form of favorable reimbursement policies will create lucrative prospects for growth in the coming years.
FMI identifies various growth drivers and restraints impacting the market’s trajectory in its recent study. The report is intended to evaluate the scope for expansion and investment feasibility in the market. Some of the key takeaways from the report are:
“Companies operating in the market are primarily focusing on research and development to find novel diagnosis methods. Their focus on offering low price therapeutic radiopharmaceuticals is expected to augur well for the market,” said a lead analyst at FMI.
Request Report Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-12424
The market for molybdenum-99 is already reeling under inadequate supply. Supply-chain disruptions are not new to the market and the unprecedented pandemic outbreak has only worsened prospects for the market’s growth in 2020.
Lockdown orders enforced across the world have caused significant disruptions in production. Partial and complete lockdown followed in the last couple of months have put a serious dent on the global GDP growth.
The negative impact of the same is felt on the molybdenum-99 market as well. North America and South Asia markets will be more hampered. Recovery however is on cards especially once the novel coronavirus passes and economies start focusing on healthcare concerns other than COVID-19.
The market has a consolidated vendor landscape. Tier-1 companies primarily boast dominance. Companies operating in the market primarily focus on research and development initiatives. Besides this, some of them are investing their resources in strategic collaborations and acquisitions to gain competitive advantage.
Other companies such as Advanced Cyclotron Systems, Inc. are focusing on research and development initiatives and establishing facilities in compliance with Good Manufacturing Practices.
Some of the companies profiled in the report are GE Healthcare, IBA, Sumitomo Corporation, Advanced Cyclotron Systems, and Siemens Healthineers.
Any Queries, ask an Expert @ https://www.futuremarketinsights.com/ask-question/rep-gb-12424
A new market research report published by Future Market Insights (FMI) on the global molybdenum-99 market offers an executive-level blueprint of the market. It offers insights into demand trends and provides analysis of opportunities over the forecast period, 2020-2030. The report examines the market through four different segments – application, end user, and region. The report also provides extensive assessment of pricing by different key market dynamics, life cycle analysis, and technologies that are being deployed in the supply molybdenum-99 and product adoption across several end-use industries.
North America, led by the US, is currently the largest market for molybdenum-99.
The global market for molybdenum-99 is forecast to surpass US$ 6.3 billion by the end of 2030. Between 2020 and 2030, the market is forecast to rise at a CAGR of 5.2%.
Some of the top companies operating in the market GE Healthcare, IBA, Sumitomo Corporation, Advanced Cyclotron Systems, Siemens Healthineers
Molybdenum-99 is used radionuclide medical imaging. It helps in noninvasively evaluating regional metabolic and phsycologic processes such as cardiac blood flow to localize the affected tissue or organ.
Molybdenum-99 primarily has demand in hospitals and diagnostic centers.
Limited supply could hamper the growth of the market in the near future. It is also expected to face threat from alternatives. Nonetheless, research and development initiatives undertaken by key players will enable growth in the market in the coming years.
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Technology Roadmap
1.5. Analysis and Recommendations
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4.1. Macro-Economic Factors
4.1.1. Global GDP Growth Outlook
4.1.2. Global Healthcare Expenditure Outlook
4.1.3. Global Pharmaceutical Market Outlook
4.2. Forecast Factors – Relevance & Impact
4.2.1. Prevalence of Cancers and Cardiovascular Diseases
4.2.2. Wide Range of Diagnostic Applications
4.2.3. Increased Focus on Centralized Pharmacies
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
5.1. Epidemiology of Various Cardiovascular Diseases
5.2. Regulatory Scenario
5.3. Reimbursement Scenario
5.4. Molybdenum-99 Service Cost Analysis
6.1. Current COVID19 Statistics and Probable Future Impact
6.2. Current GDP Projection and Probable Impact
6.3. Current Economic Projection as compared to 2008 financial analysis
6.4. COVID19 and Impact Analysis
6.4.1. Revenue By Product
6.4.2. Revenue By Country
6.5. 2020 Market Scenario
6.6. Quarter by Quarter Forecast
6.7. Projected recovery Quarter
6.8. Recovery Scenario – Short term, Midterm and Long Term Impact
The post The Global Molybdenum-99 Market is Expected to Reach US$ 6.3 Billion by end of 2030 | FMI first appeared on Market Research Blog.
The rising incidence of non-communicate diseases is creating scope for novel and advanced imaging technologies. There is immense scope for technologies that offer non-invasive yet precise diagnosis of various types of cancer and cardiovascular ailments. Future Market Insights (FMI) sees the prevailing trends to be highly favorable for the expansion of molybdenum-99 market.
Technetium-99m derived from molybdenum-99 (99Mo) is a key isotope used in radionuclide imaging. It is a part of the technology that non-invasively diagnoses regional metabolic and physiologic processes such as blood flow in the heart to zero down on the affected organ or tissue.
Molybdenum-99 is therefore used as radioisotope in various nuclear medicine diagnostic procedures. With several leading healthcare organizations intending to up their research and development initiatives, the 99Mo is expected to grow considerably in the coming years.
FMI in a recent study has projected the market to rise at a CAGR of 5.2% between 2020 and 2030. The rising willingness among patients and their families to spend on advanced healthcare will bode well for the market. Additionally, government support in the form of favorable reimbursement policies will create lucrative prospects for growth in the coming years.
FMI identifies various growth drivers and restraints impacting the market’s trajectory in its recent study. The report is intended to evaluate the scope for expansion and investment feasibility in the market. Some of the key takeaways from the report are:
“Companies operating in the market are primarily focusing on research and development to find novel diagnosis methods. Their focus on offering low price therapeutic radiopharmaceuticals is expected to augur well for the market,” said a lead analyst at FMI.
Request Report Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-12424
The market for molybdenum-99 is already reeling under inadequate supply. Supply-chain disruptions are not new to the market and the unprecedented pandemic outbreak has only worsened prospects for the market’s growth in 2020.
Lockdown orders enforced across the world have caused significant disruptions in production. Partial and complete lockdown followed in the last couple of months have put a serious dent on the global GDP growth.
The negative impact of the same is felt on the molybdenum-99 market as well. North America and South Asia markets will be more hampered. Recovery however is on cards especially once the novel coronavirus passes and economies start focusing on healthcare concerns other than COVID-19.
The market has a consolidated vendor landscape. Tier-1 companies primarily boast dominance. Companies operating in the market primarily focus on research and development initiatives. Besides this, some of them are investing their resources in strategic collaborations and acquisitions to gain competitive advantage.
Other companies such as Advanced Cyclotron Systems, Inc. are focusing on research and development initiatives and establishing facilities in compliance with Good Manufacturing Practices.
Some of the companies profiled in the report are GE Healthcare, IBA, Sumitomo Corporation, Advanced Cyclotron Systems, and Siemens Healthineers.
Any Queries, ask an Expert @ https://www.futuremarketinsights.com/ask-question/rep-gb-12424
A new market research report published by Future Market Insights (FMI) on the global molybdenum-99 market offers an executive-level blueprint of the market. It offers insights into demand trends and provides analysis of opportunities over the forecast period, 2020-2030. The report examines the market through four different segments – application, end user, and region. The report also provides extensive assessment of pricing by different key market dynamics, life cycle analysis, and technologies that are being deployed in the supply molybdenum-99 and product adoption across several end-use industries.
North America, led by the US, is currently the largest market for molybdenum-99.
The global market for molybdenum-99 is forecast to surpass US$ 6.3 billion by the end of 2030. Between 2020 and 2030, the market is forecast to rise at a CAGR of 5.2%.
Some of the top companies operating in the market GE Healthcare, IBA, Sumitomo Corporation, Advanced Cyclotron Systems, Siemens Healthineers
Molybdenum-99 is used radionuclide medical imaging. It helps in noninvasively evaluating regional metabolic and phsycologic processes such as cardiac blood flow to localize the affected tissue or organ.
Molybdenum-99 primarily has demand in hospitals and diagnostic centers.
Limited supply could hamper the growth of the market in the near future. It is also expected to face threat from alternatives. Nonetheless, research and development initiatives undertaken by key players will enable growth in the market in the coming years.
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Technology Roadmap
1.5. Analysis and Recommendations
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4.1. Macro-Economic Factors
4.1.1. Global GDP Growth Outlook
4.1.2. Global Healthcare Expenditure Outlook
4.1.3. Global Pharmaceutical Market Outlook
4.2. Forecast Factors – Relevance & Impact
4.2.1. Prevalence of Cancers and Cardiovascular Diseases
4.2.2. Wide Range of Diagnostic Applications
4.2.3. Increased Focus on Centralized Pharmacies
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
5.1. Epidemiology of Various Cardiovascular Diseases
5.2. Regulatory Scenario
5.3. Reimbursement Scenario
5.4. Molybdenum-99 Service Cost Analysis
6.1. Current COVID19 Statistics and Probable Future Impact
6.2. Current GDP Projection and Probable Impact
6.3. Current Economic Projection as compared to 2008 financial analysis
6.4. COVID19 and Impact Analysis
6.4.1. Revenue By Product
6.4.2. Revenue By Country
6.5. 2020 Market Scenario
6.6. Quarter by Quarter Forecast
6.7. Projected recovery Quarter
6.8. Recovery Scenario – Short term, Midterm and Long Term Impact
The post The Global Molybdenum-99 Market is Expected to Reach US$ 6.3 Billion by end of 2030 | FMI first appeared on Market Research Blog.
Explore more articles in the Research Reports category
